Bio-Rad Labs (NYSE: BIO) reported Q3 EPS of $0.91, $0.53 better than the analyst estimate of $0.38. Revenue for the quarter came in at $535 million versus the consensus estimate of $508 million.

GUIDANCE:

Bio-Rad Labs sees Q4 2017 revenue of $615-625 million, versus the consensus of $633 million.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.